Englewood Lab Inc (950140) fair value: what the stock is really worth
As of Oct 8, 2026: fair value of Englewood Lab Inc KRW 24,600, price KRW 8,200, upside +200.0%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Englewood Lab, Inc. engages in the research, development, manufacture, and sale of cosmetic products in the United States, Korea, Canada, China, Japan Europe, and internationally.
Show more
Englewood Lab, Inc. engages in the research, development, manufacture, and sale of cosmetic products in the United States, Korea, Canada, China, Japan Europe, and internationally. It offers masks, cleansers, and anti-aging skincare products, as well as face, eye, and body moisturizer; primers and foundations, BB and CC Cream, concealer, blush and illuminizers, bronzer highlighter, and lip care; and over the counter products, such as SPF/ACNE, personal hygiene, and skin protectant. The company was founded in 2004 and is headquartered in Totowa, New Jersey. Englewood Lab, Inc. is a subsidiary of Cosmecca Korea Co., Ltd.
Stock analysis
Englewood Lab Inc (950140) currently trades at 8,200 KRW, while our model-based Fair Value estimate is 24,600 KRW, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 57,178 KRW per share, and 23 of the 24 models we run sit above the 8,200 KRW price.
Bear case: the Asset-Based group reads lowest at 5,550 KRW, and 1 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 13,687 KRW (bear) to 30,750 KRW (bull), the price of 8,200 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Englewood Lab Inc reported revenue of 217B KRW in FY2025 versus 141M KRW in FY2021, a compound +526.7%/yr. Reported net income was 24.8B KRW in FY2025, compounding +559.7%/yr from FY2021.
Key figures
Market cap 163B KRW (≈ $122M) · P/S ratio 0.74 · Dividend yield 2.5% · Net margin 11.4% · Return on equity 20.2% · Return on assets (EBIT) 12.8% · Operating margin 16.8% · Revenue (TTM) 218B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −29% fair-value upside, at 200%, 950140 screens cheaper than that median.
Fair Value models
Bear 13,687 KRWFair Value 24,600 KRWBull 30,750 KRW
Price 8,200 KRW · Upside +200.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF11,670 KRW15,671 KRW27,346 KRW76
Growth DCF11,038 KRW16,771 KRW25,728 KRW75
EPV13,802 KRW15,252 KRW16,430 KRW74
All 24 models by family
DCF Models
FCF DCF11,670 KRW15,671 KRW27,346 KRW76
Owner Earnings15,343 KRW28,491 KRW51,436 KRW71
5Y Revenue Exit14,764 KRW25,064 KRW46,679 KRW67
5Y EBITDA Exit18,755 KRW33,117 KRW61,311 KRW69
5Y P/E Exit17,957 KRW39,105 KRW68,087 KRW65
10Y Revenue Exit13,113 KRW27,765 KRW37,459 KRW64
10Y EBITDA Exit16,062 KRW35,087 KRW68,738 KRW62
10Y P/E Exit15,564 KRW33,623 KRW63,558 KRW58
Earnings-Based
Graham-Dodd8,493 KRW59,229 KRW83,119 KRW61
Lynch FV30,600 KRW43,714 KRW56,828 KRW59
PEG = 1.030,600 KRW43,714 KRW56,828 KRW55
EPV13,802 KRW15,252 KRW16,430 KRW74
Multiples
P/E Multiple19,671 KRW26,229 KRW32,786 KRW63
P/S Multiple15,924 KRW21,233 KRW26,541 KRW58
P/B Multiple15,924 KRW21,233 KRW26,541 KRW55
EV/EBIT25,691 KRW33,685 KRW41,678 KRW66
EV/EBITDA22,617 KRW29,585 KRW36,554 KRW67
EV/Revenue15,459 KRW21,351 KRW27,244 KRW54
Asset-Based
NCAV (Graham)4,142 KRW5,550 KRW8,284 KRW54
Growth DCF
Growth DCF11,038 KRW16,771 KRW25,728 KRW75
Rev-Margin DCF16,168 KRW28,396 KRW53,890 KRW67
Economic Profit
Residual Income7,455 KRW8,788 KRW12,054 KRW74
ROIC Compounder16,801 KRW23,212 KRW27,672 KRW70
Growth Earnings
Growth-Adj P/E40,025 KRW57,178 KRW74,332 KRW65
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.86/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+162,174.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1,127.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+351.0%
Start year 2020 (pandemic). Over 10 years: +4.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.8% (2020) → 17.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +1.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 240 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Englewood Lab Inc (950140) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 24,600 KRW versus a price of 8,200 KRW, about +200% upside (undervalued).
What is the fair value of 950140?
Our model-based fair value for Englewood Lab Inc is 24,600 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 8,200 KRW.
What is the quality score of 950140?
Englewood Lab Inc has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Englewood Lab Inc (950140)?
Our model-based price target is the fair value of 24,600 KRW (as of Oct 3, 2026) from 24 valuation models. Cautious scenario 13,687 KRW, optimistic scenario 30,750 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Englewood Lab Inc stock forecast for 2026?
Our models put fair value at 24,600 KRW, about +200% upside versus a price of 8,200 KRW (undervalued). Cautious scenario 13,687 KRW, optimistic scenario 30,750 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Englewood Lab Inc (950140)?
Englewood Lab Inc reported trailing-twelve-month revenue of about 218B KRW (latest available figure, as of Oct 3, 2026).
Does Englewood Lab Inc pay a dividend?
Englewood Lab Inc currently shows a dividend yield of about 2.45% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Englewood Lab Inc (950140)?
For today's price to be fair in a discounted-cash-flow model, Englewood Lab Inc would have to grow free cash flow by +4.0 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +351.0 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of 950140 use?
Our models discount Englewood Lab Inc at 11.6 %: a base by market capitalisation (micro), damped by beta 0.28, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Englewood Lab Inc that is +4.0 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Englewood Lab Inc (950140) delivered so far?
Over the past 5 years revenue at Englewood Lab Inc grew +351.0 % a year. The price currently implies +4.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Englewood Lab Inc (950140) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Englewood Lab Inc (+4.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Englewood Lab Inc (950140)?
The free-cash-flow yield on the price is 9.61 %: that much free cash flow Englewood Lab Inc produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Englewood Lab Inc (950140)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Englewood Lab Inc it is 24,600 KRW per share (as of Oct 3, 2026), against a price of 8,200 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Englewood Lab Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 950140 trades below its calculated fair value: price 8,200 KRW, fair value 24,600 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 950140?
No. The price is what the market pays today (8,200 KRW); the fair value is what the company's own numbers justify (24,600 KRW). For Englewood Lab Inc the two are 16,400 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Englewood Lab Inc worth?
The market values Englewood Lab Inc at about 163B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 8,200 KRW; our models calculate a fair value of 24,600 KRW per share.
What do the bullish and bearish scenarios say about 950140?
Our models span a range for Englewood Lab Inc: cautious scenario 13,687 KRW, base 24,600 KRW, optimistic 30,750 KRW per share (as of Oct 3, 2026, price 8,200 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Englewood Lab Inc (950140)?
Balance-sheet figures for Englewood Lab Inc (as of Oct 3, 2026): return on equity 20.2%, debt of 0.01 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 950140 from its 52-week high?
Englewood Lab Inc trades at 8,200 KRW, about 48% below its 52-week high of 15,730 KRW and 6% above the low of 7,720 KRW (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of 24,600 KRW is for.
Which stocks are comparable to Englewood Lab Inc?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, The Estée Lauder Companies Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Englewood Lab Inc stock attractive at the current price?
The data as of Oct 3, 2026: price 8,200 KRW, calculated fair value 24,600 KRW (+200%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 950140 calculated?
We run Englewood Lab Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 24,600 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Englewood Lab Inc currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Englewood Lab Inc (950140)?
The closing price on Oct 8, 2026 was 8,200 KRW. Our model-based fair value is 24,600 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Englewood Lab Inc right now?
The price is below even our cautious bear case (13,687 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (13,687 KRW to 30,750 KRW) leaves room in how you read the outcome.
Key figures of Englewood Lab Inc
How large is the market capitalisation of Englewood Lab Inc (950140)?
The market capitalisation of Englewood Lab Inc is 163B KRW (≈ $122M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Englewood Lab Inc (950140)?
The price-to-sales ratio of Englewood Lab Inc is 0.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Englewood Lab Inc (950140)?
The dividend yield of Englewood Lab Inc is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Englewood Lab Inc (950140)?
The net margin of Englewood Lab Inc is 11.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Englewood Lab Inc (950140)?
The return on equity (ROE) of Englewood Lab Inc is 20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Englewood Lab Inc (950140)?
On an EBIT basis the return on assets of Englewood Lab Inc is 12.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Englewood Lab Inc (950140)?
The operating margin of Englewood Lab Inc is 16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Englewood Lab Inc (950140)?
Revenue at Englewood Lab Inc is growing −12.3% versus a year earlier (3y avg +1,127%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Englewood Lab Inc (950140)?
Earnings per share at Englewood Lab Inc are growing +123% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Englewood Lab Inc (950140) carry?
The net debt of Englewood Lab Inc is 11.5B KRW (fiscal year 2022, ≈ 0.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Englewood Lab Inc in the live analysis
One click puts Englewood Lab Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
